December 21, 2018
Novartis in $2.1 billion Endocyte buy, adds to its oncology pipeline
In addition to yesterda’s announcement of moving to buy CAR-T cell producer CellforCure from LFB, Novartis today announced that it acquired another biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment, the US based Endocyte, Inc.